Cargando…
Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis
INTRODUCTION: Atopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with complex immunopathogenesis characterized by a dominant T(H)2 response. Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that subsequently blocks IL-4 and IL-13 signaling. It has recently been app...
Autores principales: | Eshtiaghi, Panteha, Gooderham, Melinda J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826246/ https://www.ncbi.nlm.nih.gov/pubmed/29503598 http://dx.doi.org/10.2147/CE.S133661 |
Ejemplares similares
-
Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021) -
Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
por: Lytvyn, Yuliya, et al.
Publicado: (2023) -
Dupilumab for atopic dermatitis
Publicado: (2019) -
Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis
por: Awosika, Olabola, et al.
Publicado: (2018) -
Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)